Skip to main content
Treatment with the immune checkpoint inhibitor atezolizumab (Tecentriq) following surgical resection and chemotherapy significantly improved disease-free survival (DFS) compared with best supportive care (BSC) alone in patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and PD-L1 tumor composite score ≥1%, according to interim results from the phase 3 IMpower010 clinical trial, which were presented at the ASCO 2021 virtual annual meeting. Read More ›

Researchers and clinicians continue to make advances in the treatment of cancer. In 2021, despite the COVID-19 pandemic, there have been many exciting developments in biomarker testing and other diagnostics, treatment approaches and targets, and other aspects of cancer care. Read More ›

On May 28, 2021, the FDA accelerated the approval of sotorasib (Lumakras; Amgen), an oral KRAS inhibitor of the RAS GTPase family, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) associated with KRAS G12C mutation, as determined by an FDA-approved test, after ≥1 systemic therapies. The FDA granted sotorasib orphan drug and breakthrough therapy designations. Read More ›

On May 21, 2021, the FDA accelerated the approval of amivantamab-vmjw (Rybrevant; Janssen/Johnson & Johnson), a bispecific antibody targeting mutations in the EGFR and MET pathways, for adults with non–small-cell lung cancer (NSCLC) that is associated with EGFR exon 20 insertion mutations, as detected by the FDA-approved Guardant360 CDx test, which was approved on the same day as a companion diagnostic for amivantamab. The FDA had granted amivantamab a breakthrough therapy designation for this indication. Read More ›

Approximately 13% of patients with lung adenocarcinomas harbor KRAS p.G12C mutations. In the phase 2 CodeBreaK 100 clinical trial, the responses to sotorasib in patients with advanced non–small-cell lung cancer (NSCLC) and KRAS p.G12C mutation were early, deep, and durable, according to Bob T. Li, MD, PhD, MPH, Medical Oncologist, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. He presented the study results at the 2021 International Association for the Study of Lung Cancer meeting. Read More ›

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›

Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›

The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›

A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers. Read More ›

Page 5 of 16